Related Experiment Video
Updated: Mar 6, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C virus infection
Michael P Manns1,2,3, Maria Buti4, Ed Gane5
1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Insights
Hepatitis C virus (HCV) infection, affecting millions globally, can be cured in over 90% of patients using direct-acting antiviral agents (DAAs). Effective control relies on screening, treatment access, and prevention strategies until a vaccine is developed.
Area of Science:
- Hepatology and Virology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) is a global health concern, causing chronic liver disease, cirrhosis, and liver cancer.
- An estimated 64–103 million individuals worldwide are chronically infected with HCV.
- Key transmission routes include unsafe injection practices and iatrogenic infections in high-prevalence regions.
Purpose of the Study:
- To review the current landscape of Hepatitis C virus diagnosis and treatment.
- To highlight the efficacy of direct-acting antiviral agents (DAAs) in curing HCV infection.
- To emphasize strategies for controlling the HCV pandemic in the absence of a vaccine.
Main Methods:
- Diagnostic methods include HCV antibody testing, RNA quantification, genotyping, and resistance-associated substitution analysis.
- Treatment involves direct-acting antiviral agents (DAAs) targeting essential HCV proteins (NS3/4A protease, NS5A, NS5B polymerase).
- Combination therapy with two or three DAAs is employed for treatment.
Main Results:
- DAA combination therapies achieve sustained virological response (SVR12), indicating a cure, in over 90% of patients.
- These treatments are effective even in previously difficult-to-treat populations.
- The development of DAAs has revolutionized HCV management.
Conclusions:
- HCV infection is highly curable with modern DAA therapies.
- Control of the HCV pandemic necessitates a multi-pronged approach: treatment-as-prevention, robust screening, and equitable access to care.
- Ongoing efforts are crucial until a prophylactic vaccine becomes available.
Abstract:
Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage, which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and 103 million people are chronically infected. Major risk factors for this blood-borne virus infection are unsafe injection drug use and unsterile medical procedures (iatrogenic infections) in countries with high HCV prevalence. Diagnostic procedures include serum HCV antibody testing, HCV RNA measurement, viral genotype and subtype determination and, lately, assessment of resistance-associated substitutions. Various direct-acting antiviral agents (DAAs) have become available, which target three proteins involved in crucial steps of the HCV life cycle: the NS3/4A protease, the NS5A protein and the RNA-dependent RNA polymerase NS5B protein. Combination of two or three of these DAAs can cure (defined as a sustained virological response 12 weeks after treatment) HCV infection in >90% of patients, including populations that have been difficult to treat in the past. As long as a prophylactic vaccine is not available, the HCV pandemic has to be controlled by treatment-as-prevention strategies, effective screening programmes and global access to treatment.
